Turn­ing Point tracks an im­pres­sive ORR rate in NSCLC — but shares skid low­er on sec­ond look

CHICA­GO — Fresh off of a $166 mil­lion IPO raise, Turn­ing Point Ther­a­peu­tics $TP­TX joined the open­ing-day fes­tiv­i­ties at AS­CO with an up­date on their lead drug re­potrec­tinib — which they plan to pitch for an ear­ly ap­proval for ROS1+ ad­vanced non-small cell lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.